Skip to main content
Premium Trial:

Request an Annual Quote

Amgen, Selexis Expand Deal to Include Evaluation of Mammalian Cell Line

NEW YORK (GenomeWeb News) – Amgen expanded an R&D licensing agreement to include the evaluation of Selexis' Sure Cho-M Cell Line.

Under the terms of the deal announced today by Selexis, Amgen will assess the cell line in conjunction with the Selexis SUREtech Vectors for improved R&D. Sure Cho-M Cell Line is a mammalian cell line derived from CHO-K1 cells and is for producing therapeutic recombinant proteins and monoclonal antibodies.

Financial and other terms of the deal were not disclosed.

Today's announcement builds on a relationship between Selexis and Amgen reaching back to 2004, Igor Fisch, president and CEO of Selexis, said in a statement.

"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding, and stable," he said. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently."

Based in Geneva, Selexis provides technologies for drug discovery, cell line development, and scale-up to manufacturing of therapeutic proteins.